# Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan

> **NCT02402699** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 3 (actual)

## Conditions studied

- Advanced Melanoma
- Hepatitis B
- Hepatitis C

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02402699
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-15
- **Primary completion:** 2017-03-23
- **Final completion:** 2017-03-23
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2022-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02402699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02402699, "Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02402699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*